AtriCure (ATRC) Q2 FY26 earnings call

AtriCure delivered a robust second quarter, marked by strong double-digit revenue growth and significant profitability expansion, driven by new product adoption and manufacturing efficiencies. The company is ahead of its long-range plan for bottom-line performance and is actively advancing key clinical trials like Box NOAAF and LEAPS, which are expected to be major catalysts for future market expansion. Despite competitive entries in the appendage management market and pressure in MI ablation, management remains confident in its innovation, clinical evidence, and specialized field teams.